127 related articles for article (PubMed ID: 26874673)
21. Using the clinical information system and self-supervision to rationalize the need for antibiotic stewardship: An interventional study in a 2000-bed university hospital.
Viala B; Villiet M; Redor A; Didelot MN; Makinson A; Reynes J; Le Moing V; Morquin D
Int J Antimicrob Agents; 2021 Jan; 57(1):106233. PubMed ID: 33232732
[TBL] [Abstract][Full Text] [Related]
22. Causes of non-adherence to therapeutic guidelines in severe community-acquired pneumonia.
Gattarello S; Ramírez S; Almarales JR; Borgatta B; Lagunes L; Encina B; Rello J;
Rev Bras Ter Intensiva; 2015; 27(1):44-50. PubMed ID: 25909312
[TBL] [Abstract][Full Text] [Related]
23. Emergence and spread of carbapenem-resistant strains of Acinetobacter baumannii in a tertiary-care hospital in Poland.
Wroblewska MM; Towner KJ; Marchel H; Luczak M
Clin Microbiol Infect; 2007 May; 13(5):490-6. PubMed ID: 17331123
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system.
Ahmad F; Pogue JM; Marchaim D; Chopra T; Bheemreddy S; Lee J; Mudegowdra NS; Chaudhry A; Kaye KS
J Infect Public Health; 2014 Feb; 7(1):50-3. PubMed ID: 24210246
[TBL] [Abstract][Full Text] [Related]
25. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting.
Lew KY; Ng TM; Tan M; Tan SH; Lew EL; Ling LM; Ang B; Lye D; Teng CB
J Antimicrob Chemother; 2015 Apr; 70(4):1219-25. PubMed ID: 25473028
[TBL] [Abstract][Full Text] [Related]
26. Clinical epidemiology of carbapenem-resistant enterobacteriaceae in community hospitals: a case-case-control study.
Lee GC; Lawson KA; Burgess DS
Ann Pharmacother; 2013 Sep; 47(9):1115-21. PubMed ID: 24259725
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
Park SH; Choi SM; Chang YK; Lee DG; Cho SY; Lee HJ; Choi JH; Yoo JH
J Antimicrob Chemother; 2014 Oct; 69(10):2848-56. PubMed ID: 24928854
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for acquisition of carbapenem-resistance during treatment with carbapenem in the intensive care unit: a prospective study.
Labaste F; Grossac J; Bounes FV; Conil JM; Ruiz S; Seguin T; Grare M; Fourcade O; Minville V; Georges B
Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2077-2085. PubMed ID: 31482416
[TBL] [Abstract][Full Text] [Related]
29. [Can the antibiotic prescription practice in a hospital be influenced by in-house guidelines? An interventional study at the University Hospital Halle (Saale), Germany].
Lübbert C; Schumacher U; Stareprawo S; Claus J; Heeß-Erler G; Fiebig C; de With K; Wilhelms D; Kekulé AS; Klöss T; Moritz S;
Dtsch Med Wochenschr; 2014 Dec; 139(50):2578-84. PubMed ID: 25271804
[TBL] [Abstract][Full Text] [Related]
30. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
31. Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE).
Goodman KE; Simner PJ; Tamma PD; Milstone AM
Expert Rev Anti Infect Ther; 2016; 14(1):95-108. PubMed ID: 26535959
[TBL] [Abstract][Full Text] [Related]
32. Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae.
Prinapori R; Guinaud J; Khalil A; Lecuyer H; Gendrel D; Lortholary O; Nassif X; Viscoli C; Zahar JR
Am J Infect Control; 2013 Mar; 41(3):259-60. PubMed ID: 23062579
[TBL] [Abstract][Full Text] [Related]
33. Repeated nationwide point-prevalence surveys of antimicrobial use in Swedish hospitals: data for actions 2003-2010.
Skoog G; Struwe J; Cars O; Hanberger H; Odenholt I; Prag M; Skärlund K; Ulleryd P; Erntell M
Euro Surveill; 2016 Jun; 21(25):. PubMed ID: 27367646
[TBL] [Abstract][Full Text] [Related]
34. Successful containment of carbapenem-resistant Enterobacteriaceae by strict contact precautions without active surveillance.
Kim NH; Han WD; Song KH; Seo HK; Shin MJ; Kim TS; Park KU; Ahn S; Yoo JS; Kim ES; Kim HB
Am J Infect Control; 2014 Dec; 42(12):1270-3. PubMed ID: 25465255
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal outbreak of VIM-1-carbapenemase-producing Enterobacter cloacae in intensive care unit, University Hospital Centre Split, Croatia.
Novak A; Goic-Barisic I; Andrasevic AT; Butic I; Radic M; Jelic M; Rubic Z; Tonkic M
Microb Drug Resist; 2014 Oct; 20(5):399-403. PubMed ID: 24716493
[TBL] [Abstract][Full Text] [Related]
36. Widespread increase of empirical carbapenem use in acute care hospitals in Catalonia, Spain.
Grau S; Fondevilla E; Echeverría-Esnal D; Alcorta A; Limon E; Gudiol F;
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Jan; 37(1):36-40. PubMed ID: 29703463
[TBL] [Abstract][Full Text] [Related]
37. The purpose and appropriateness of carbapenem use in a single university hospital, 2009-2013.
Yoon D; Koo HL; Choe PG; Song KH; Park WB; Bang JH; Kim ES; Park SW; Kim HB; Oh MD; Kim NJ
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):863-5. PubMed ID: 26932319
[TBL] [Abstract][Full Text] [Related]
38. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
Huang SS; Lee MH; Leu HS
J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
[TBL] [Abstract][Full Text] [Related]
39. Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?
Barbier F; Pommier C; Essaied W; Garrouste-Orgeas M; Schwebel C; Ruckly S; Dumenil AS; Lemiale V; Mourvillier B; Clec'h C; Darmon M; Laurent V; Marcotte G; Lucet JC; Souweine B; Zahar JR; Timsit JF;
J Antimicrob Chemother; 2016 Apr; 71(4):1088-97. PubMed ID: 26755492
[TBL] [Abstract][Full Text] [Related]
40. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
